Avalon GloboCare Corp.ALBTEarnings & Financial Report
Avalon GloboCare Corp. is a global biotechnology and healthcare service provider specializing in cell and gene therapy, regenerative medicine solutions, and translational medical research. It operates across North America and Asia, serving clinical, research and commercial healthcare stakeholders with tailored offerings.
ALBT Q3 FY2025 Key Financial Metrics
Revenue
$350.1K
Gross Profit
N/A
Operating Profit
$-76.2K
Net Profit
$-254.3K
Gross Margin
N/A
Operating Margin
-21.8%
Net Margin
-72.6%
YoY Growth
1.4%
EPS
$-0.06
Avalon GloboCare Corp. Q3 FY2025 Financial Summary
Avalon GloboCare Corp. reported revenue of $350.1K (up 1.4% YoY) for Q3 FY2025, with a net profit of $-254.3K (up 84.9% YoY) (-72.6% margin).
Key Financial Metrics
| Total Revenue | $350.1K |
|---|---|
| Net Profit | $-254.3K |
| Gross Margin | N/A |
| Operating Margin | -21.8% |
| Report Period | Q3 FY2025 |
Avalon GloboCare Corp. Annual Revenue by Year
Avalon GloboCare Corp. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.3M).
Avalon GloboCare Corp. Quarterly Revenue & Net Profit History
Avalon GloboCare Corp. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $350.1K | +1.4% | $-254.3K | -72.6% |
| Q2 FY2025 | $350.4K | +6.9% | $-13.5M | -3840.9% |
| Q1 FY2025 | $349.8K | +11.2% | $-2.5M | -709.6% |
| Q4 FY2024 | $345.8K | +7.6% | N/A | N/A |
| Q3 FY2024 | $345.2K | +4.2% | $-1.7M | -486.5% |
| Q2 FY2024 | $327.9K | +6.8% | $-2.1M | -650.2% |
| Q1 FY2024 | $314.6K | +6.2% | $-1.4M | -434.7% |
| Q4 FY2023 | $321.3K | +8.4% | $-9.6M | -2973.7% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $321321 | $314588 | $327887 | $345159 | $345769 | $349800 | $350406 | $350099 |
| YoY Growth | 8.4% | 6.2% | 6.8% | 4.2% | 7.6% | 11.2% | 6.9% | 1.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $20.6M | $20.3M | $19.5M | $19.6M | N/A | $10.6M | $8.0M | $9.1M |
| Liabilities | $13.2M | $14.3M | $15.1M | $14.1M | N/A | $14.5M | $15.1M | $13.6M |
| Equity | $7.4M | $6.1M | $4.4M | $5.4M | N/A | $-3.9M | $-7.1M | $-4.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-796316 | $-915709 | $-1.1M | $-1.9M | $-1.1M | $-1.8M | $-1.2M | $-1.4M |